CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team


Particles Comprising Luminescent Lanthanide Complexes



Statut des brevets

European priority patent application n° 13305291.0 filed on 14/03/2013 and entitled “Particles comprising luminescent lanthanide complexes”


Stéphane PETOUD


Statut commercial

Open for Exclusive or non-exclusive license


Centre de biophysique moléculaire (CBM, UPR4301), Orléans, France



Liponanoparticles (liposomes, synthetic lipoproteins, etc) have been widely explored as drug delivery devices; one example is Doxil, the clinically used liposome formulation of doxorubicin. Nevertheless, the in vivo, real time follow-up of drug release from these particles by imaging techniques remains an important challenge. The invention covers the design and the preparation of novel theranostic lipoparticles (liposomes, lipoproteins or other nanoparticles) which allow the visualization of drug release by optical imaging.


Among the different constituents that may build up these liponanoparticles, amphiphilic luminescent lanthanide complexes and a drug molecule have to be present. Depending on their lipophilic properties, the incorporated drug molecules may be localized either in the lipidic bilayer or in the aqueous core of the particles. In order to observe the luminescence of lanthanide complexes, the presence of a chromophore (antenna) is required that is capable of absorbing the excitation energy and transferring it to the lanthanide. Our invention consists of using the drug molecules to act as an antenna for the lanthanide luminescence. As a consequence, the release of the drug from the liponanoparticles will lead to the change of the luminescence signal thus allowing a direct follow-up of the drug release. Many anti-cancer agents contain a conjugated aromatic system and are capable of sensitizing lanthanide luminescence. For those drugs, we propose to create innovative image-guided therapies exploiting optical imaging based on drug-sensitized luminescence.

The drug acts as an antenna to sensitize lanthanide luminescence. The proximity of the drug and the lanthanide is a prerequisite for sensitization. As soon as the drug is released from the particle, this condition is not met any more, leading to the decrease of lanthanide luminescence.


Proof of concept has been obtained with doxorubicin and mitoxantrone in liposome formulations containing amphiphilic Ln3+ complexes which emit in the near IR. These particles have been detected in vivo in mice with fluorescence optics of a macroscope. The excitation wavelengths for doxorubicin, 600 nm, and for mitoxantrone, 660-700nm, are compatible with biological applications.


In both imaging and drug delivery, the control of the in vivo integrity of the liponanoparticles and the monitoring of the release of the drug at the site of interest remains a challenge and calls for innovative in vivo imaging applications. We propose a fundamentally novel optical imaging approach to address this unmet need by exploiting sensitized lanthanide luminescence.

For further information, please contact us (Ref 04400-01)

Besoin de plus d'informations ?

Nous contacter


  • This field is for validation purposes and should be left unchanged.

Les brevets les plus récents